Thesan Pharmaceuticals has closed a $16 million Series A financing, co-led by Novo Ventures and Novartis Venture Funds. The company focuses on the development of novel approaches for the treatment of dermatological disorders.
You are browsing the archive for Novo Ventures - peHUB.
Tobira Therapeutics, a developer of innovative antiretroviral therapies for HIV, has appointed three executives in the finance, clinical and pharmaceutical sciences functions. Caroline Loewy joins the company as executive vice president and chief financial officer, Jeff Enejosa, M.D., as senior director, clinical research, and Mark Menning as director, pharmaceutical sciences. Tobira has financial backing from [...]
Alder BioPharmaceuticals closed a $38 million Series D round led by a new investor—Novo Ventures—and including existing Alder investors Sevin Rosen Funds, Ventures West, WRF Capital, H.I.G. Ventures, Delphi Ventures and TPG Biotech. Novo’s Peter Bisgaard will join Alder’s board as part of the deal. Alder BioPharma is based in Washington and is develops products [...]
Elevation Pharmaceuticals Inc. said Wednesday that it had closed $30 million in Series B financing led by new investor Novo Ventures. The company, which develops aerosol therapy for patients living with chronic obstructive pulmonary disease, was also backed in the round by previous investors including Canaan Partners, TPG Biotech, Care Capital and Mesa Verde Venture Partners. As part of the deal, Novo Ventures’ Heath Lukatch joins the company’s board. Elevation is based in San Diego, Calif.
Zurich-based Delenex Therapeutics has closed on an additional $13 million euro ($19.3 million) to bring its Series A round to 23.5 million euro ($34.8 million). Novo Ventures led the latest tranche, with participation from SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners. Delenex is a biotech company developing therapeutic antibody fragments for diseases with high unmet need.
Vienna-based biopharma company f-star GmbH has raised 15 million euro ($21.7 million) in a new financing round led by SR One, the corporate venture capital arm of GlaxoSmithKline. Existing shareholder Atlas Venture, Aescap Venture, Novo Ventures, TVM Capital, Merck Serono Ventures and MP Healthcare Venture Management also participated in the round. As a result, SR One Partner Dr Deborah Harland and Dr Axel Polack of TVM Capital will join f-star’s Supervisory Board.